Jump to content
Please Check, and if Necessary, Update Your BB Account Email Address as a Matter of Urgency ×
New Forum: Celebrating 20 Years of Support - Everyone is Invited! ×
  • Please Donate

    Donate with PayPal button

    For nearly 20 years, BenzoBuddies has assisted thousands of people through benzodiazepine withdrawal. Help us reach and support more people in need. More about donations here.

Study, May/19:How do potentially inappropriate medications & polypharmacy...


[La...]

Recommended Posts

The full title of this UK study is "How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study."

 

https://www.ncbi.nlm.nih.gov/pubmed/31092652

 

Abstract

 

OBJECTIVES:

 

To test whether the use of potentially inappropriate central nervous system acting medications, proton pump inhibitors (PPIs) or polypharmacy are associated with mortality in cognitively impaired older adults and whether frailer people are at greater risk of harm.

 

SETTING:

 

A cohort study nested within the Cognitive Function and Ageing Study II, a population representative cohort study of the older population in Cambridgeshire, Nottingham and Newcastle, UK.

 

PARTICIPANTS:

 

A total of 1154 cognitively impaired participants, aged 65 years or older.

 

EXPOSURES:

 

Any use of antipsychotics, antidepressants, other anticholinergic medication, benzodiazepines or PPIs, polypharmacy (5-9) and hyperpolypharmacy (≥10 reported medications) were ascertained at baseline. Frailty was assessed using the Fried criteria.

 

PRIMARY OUTCOME:

 

Mortality up to 8 years follow-up. HRs associated with potentially inappropriate medication (PIM), frailty and their interaction were estimated adjusting for covariates.

 

RESULTS:

 

Within the sample, 44% were taking one or more PIM. Apart from antipsychotics (adjusted HR=3.24, 95% CI 1.83 to 5.73), use of specific PIM was not associated with greater subsequent mortality. Polypharmacy (HR=1.17, 95% CI 0.95 to 1.45) and hyperpolypharmacy were associated with mortality (HR=1.60, 95% CI 1.16 to 2.22). Being frail (HR=1.90, 95% CI 1.32 to 2.72) or prefrail (HR=1.56, 95% CI 1.10 to 2.20) was associated with increased mortality. There was some evidence that the HR for polypharmacy on mortality was lower among frailer individuals, but the overall polypharmacy by frailty interaction was not statistically significant (p=0.102).

 

CONCLUSIONS:

 

For those with cognitive impairment, greater concern should be afforded to the number of medications than the prescription of specific classes. Frailer individuals may have a lower relative risk of mortality associated with polypharmacy than less frail individuals.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Who's Online (See full list)

    • [An...]
    • [fa...]
    • [Ka...]
    • [Da...]
    • [Pa...]
    • [Fa...]
    • [...]
    • [Ro...]
    • [le...]
    • [mo...]
    • [Ch...]
    • [Si...]
    • [Mi...]
    • [...]
    • [Ca...]
    • [Ta...]
    • [jo...]
    • [Ki...]
    • [Ga...]
    • [Pi...]
    • [Sc...]
    • [ca...]
    • [in...]
    • [...]
    • [Sc...]
    • [Re...]
    • [kn...]
    • [...]
    • [Ap...]
    • [Ev...]
    • [Mo...]
    • [SB...]
    • [Bl...]
    • [ro...]
    • [Be...]
    • [mc...]
    • [be...]
    • [Av...]
    • [El...]
    • [bi...]
    • [jo...]
    • [Kl...]
    • [Ma...]
×
×
  • Create New...